BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

NK:IO Secures £1.6M Innovate UK Grant for Pioneering Cancer Therapy

Grant award of £1.6M supports program of development work with Cell and Gene Therapy Catapult NK:IO’s platform, based on pionee...

July 11, 2023 | News

3D bioprinting technology to be used for removing cancer cells

□ A three-dimensional (3D) bioprinting technology capable of eliminating cancer cells using the function of immune cells has been developed for t...

July 11, 2023 | News

280 Bio receives IND approval from the FDA for YL-17231

80Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug ...

July 10, 2023 | News

Hexvix® Completes Phase III Bridging Trial Enrollment for Bladder Cancer

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

July 10, 2023 | News

GeneQuantum Healthcare and Aimed Bio collaborate to develop 5 innovative ADC drugs

Since April of last year, GeneQuantum and Aimed Bio have been collaborating on the joint development of a FGFR3-targeting ADC named GQ1011/AMB302. The prog...

July 07, 2023 | News

I-Mab Publishes Givastomig, a Claudin18.2 x 4-1BB Bispecific Antibody, in JITC

Givastomig is engineered to bind to CLDN18.2-expressing cancer cells and co-stimulatory receptor 4-1BB on adjacent T cells, with the aim of activating...

July 06, 2023 | News

FDA Approves Cu-64 SAR-bisPSMA Phase III Trial for Prostate Cancer

FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on&n...

July 05, 2023 | News

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

The pivotal clinical trial approved in China will evaluate the efficacy and safety of Glecirasib as a single agent for the second line treatment ...

July 05, 2023 | News

Innovent and IASO Bio Receive NMPA Approval for FUCASO®, a Fully-human BCMA CAR-T Therapy for Multiple Myeloma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

July 03, 2023 | News

Thermo Fisher Scientific Introduces Tumor Culture Medium for Faster Cancer Treatment Development

Thermo Fisher Scientific, a global leading company in science services, today announced the launch of the Gibco™ OncoPro™ tumor media kit. *, t...

June 29, 2023 | News

Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET™ technology

By using this cutting-edge imaging technology in preclinical studies, Oncodesign Services’ team hopes to gain insights of the predictive effectivenes...

June 29, 2023 | News

INOVIQ's SubB2M/CA15-3 Breast Cancer Test Shows Excellent Clinical Data

INOVIQ's SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) The...

June 28, 2023 | News

CStone Receives China NMPA Approval for GAVRETO® in First-Line Treatment of RET Fusion-Positive Lung Cancer.

The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks the third indication of GAVRETO in Mainland Chi...

June 27, 2023 | News

Prenetics and Prof. Dennis Lo Launch US$200m Joint Venture "Insighta" for Multi-Cancer Early Detection

- Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics w...

June 26, 2023 | News

Stay Connected